


PRECEPTORSHIP



Un confronto sulla gestione delle malattie linfoproliferative al Sant'Orsola di Bologna

Bologna, NH DE LA GARE, 6 ottobre 2025

IL LINFOMA FOLLICOLARE: MANAGEMENT ED APPROCCIO TERAPEUTICO DEI PAZIENTI IN PRIMA LINEA E DEI PAZIENTI RICADUTI/REFRATTARI

Alessandro Broccoli

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico «Sant'Orsola-Malpighi»
Department of Medicine and Surgery, University of Bologna, Italy
Institute of Hematology «L. e A. Seràgnoli», Bologna, Italy



Disclosures: ALESSANDRO BROCCOLI

Company name	Research support	Consultant	Stockholder	Speakers bureau	Advisory board	Other
Sandoz	X				X	X
Gilead				X	X	X
Merck	X					X
Janssen	X			X		X
Takeda		X		X	X	X
Kyowa Kirin	X			X	X	X
Incyte						X
Recordati						X
Astra Zeneca				X	X	
Roche				X		X
GlaxoSmithKline		X		X	X	
BeOne	X			X	X	X
Eli Lilli						X




Follicular lymphoma: an introduction

- **Follicular lymphoma:** the paradigm of indolent lymphomas.
- Slow-growing disease, rarely with systemic symptoms.
- High response rates to first-line standard treatments (immuno-chemotherapy) but with tendency to relapse or transformation.
- Progression-free survival, disease-free survival and time-to-next treatment intervals (rather than overall survival) to be considered to compare different treatment policies.
- **Stage** (limited vs diffuse disease spreading): dictates the initial management of the patient (type of treatment and possibly timing).
- **Symptomatic disease (i.e. tumor burden):** dictates treatment timing (watch and wait vs immuno-chemotherapy initiation).



Epidemiology


Lymphoma incidence, survival and prevalence
2004–2014: sub-type analyses from the UK’s
Haematological Malignancy Research
Network



Smith A. *Br J Cancer*, 2015; 112: 1575-1584



Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial



Kaplan-Meier estimates of progression-free survival (A), time to next antilymphoma treatment (B), time to next chemotherapy (C), and overall survival (D) from randomisation with rituximab maintenance versus observation

Salles G. *Lancet*, 2011; 377: 42-51



Obinutuzumab for the First-Line Treatment of Follicular Lymphoma



